Experienced in Hashimoto Thyroiditis

Brigitte T. Wildemann

Heidelberg, BW, DE 
Experienced in Hashimoto Thyroiditis
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Brigitte Wildemann practices in Heidelberg, Germany. Ms. Wildemann is rated as an Experienced expert by MediFind in the treatment of Hashimoto Thyroiditis. Her top areas of expertise are Optic Neuritis, Transverse Myelitis, Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, and Osteotomy.

Her clinical research consists of co-authoring 231 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Hashimoto Thyroiditis.

Gender
Female

Locations

Heidelberg, BW, Germany
Other Locations
Freiburg, BW, Germany
Berlin, BE, Germany
Berg, BW, Germany
Hannover, NI, Germany
Mannheim, BW 68167, Germany
Jena, TH 07747, Germany
Gutenberg, RP, Germany
Goettingen, NI, Germany
Luebeck, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Teriflunomide [Aubagio]
Study Phase: Phase 3
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)
A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)
Enrollment Status: Completed
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trials

231 Total Publications

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wildemann's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile